Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers

Sponsor
Federation Francophone de Cancerologie Digestive
Study ID
NCT02384759
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
65 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is what the FFCD 11-01 - PRODIGE 25 trial proposes to study, as a preliminary for strategic studies evaluating the usefulness of including targeted therapeutics from the first line with aflibercept +/- LV5FU2.

Key Dates

Start date
May 31, 2015
Status verified
Jul 2024
Primary completion
Jun 30, 2021
Completion
Jun 30, 2021

Study Design

Enrollment
117 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: A
    Aflibercept + LV5FU2
  • Active Comparator: B
    LV5FU2

Primary Outcome Measure

The Primary Objective Was the Percentage of Patients Alive and Without Progression 6 Months After the Randomization. [ Time Frame: At 6 months after randomization ]

Related Studies